A New Drug That Boosts the Brain's Own Cannabis-Like Chemicals May Help Treat Migraine Pain

What the researchers found

The brain's meninges naturally contain endocannabinoids (2-AG and AEA) that can quiet pain-signaling nerve fibers. AKU-005, which blocks the enzymes that break down both endocannabinoids, significantly reduced nerve excitation triggered by potassium chloride stimulation in rat and human tissue. The pain-relieving effect worked through CB1 receptors, not TRPV1 channels. Interestingly, 2-AG levels were much higher than AEA at baseline, suggesting 2-AG provides ongoing pain suppression while AEA kicks in on demand when nerves become active.

Why it matters

Current migraine treatments have significant limitations. This study provides early evidence that boosting the body's own endocannabinoid system — rather than using external cannabinoids — could offer a targeted approach to migraine pain at its source in the meninges.

The numbers in context

- Basal 2-AG levels exceeded AEA levels in both rat and human meninges

- KCl-induced depolarization doubled AEA levels

- AKU-005 significantly decreased KCl-induced nerve fiber excitation

- CB1 antagonist AM-251 reversed the anti-nociceptive effects of both AKU-005 and AEA

- TRPV1 antagonist capsazepine did not reverse AEA's inhibitory action

How the study worked

Researchers measured MAGL and FAAH enzyme activity and endocannabinoid levels in rat meninges (from P38-P40 Wistar rats) and human meninges (from elderly neurosurgery patients). They tested AKU-005's effects on nerve fiber excitability using paired KCl-induced spiking protocols, validating results with direct application of AEA or 2-AG. Receptor involvement was confirmed using CB1 antagonist AM-251 and TRPV1 antagonist capsazepine.

Who was studied

Rat meningeal tissue (P38-P40 Wistar rats) and human meningeal tissue from elderly neurosurgery patients

What this study cannot tell us

This was an in vitro study using isolated tissue, not whole animals or humans. Human tissue came from elderly non-migraine patients undergoing neurosurgery, which may not represent typical migraine sufferers. The study demonstrates proof of concept but cannot confirm whether AKU-005 would be effective or safe as an oral migraine treatment in people.

How to read the evidence

In vitro laboratory study using isolated animal and human tissue. Provides mechanistic evidence but is far from clinical application.

When this study was published

Published in 2023. Represents current preclinical research into endocannabinoid-based migraine therapies.

The bigger picture

The endocannabinoid system is increasingly recognized as a key regulator of pain signaling. Rather than introducing external cannabinoids like THC, drugs like AKU-005 aim to amplify the body's own endocannabinoid tone. This approach could potentially avoid the psychoactive effects of cannabis while still targeting pain at its neurological source.

Questions still open

• Would AKU-005 be effective when taken orally as a migraine preventive or acute treatment?
• Do migraine patients have lower baseline endocannabinoid levels in their meninges compared to non-migraine individuals?
• Could long-term MAGL/FAAH inhibition lead to tolerance or downregulation of CB1 receptors?

Read the original research

Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.

The journal of headache and pain, 24(1), 38

Citation

Della Pietra, Adriana; Krivoshein, Georgii; Ivanov, Konstantin; Giniatullina, Raisa; Jyrkkänen, Henna-Kaisa; Leinonen, Ville; Lehtonen, Marko; van den Maagdenberg, Arn M J M; Savinainen, Juha; Giniatullin, Rashid. (2023). Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.. The journal of headache and pain, 24(1), 38. https://doi.org/10.1186/s10194-023-01568-3